Proteina, an AI new drug development corporations based on protein interactions, said on the 13th that its obesity and diabetes treatment candidate PRT1309 was selected for an oral presentation at the American Diabetes Association (ADA 2026).
The American Diabetes Association (ADA) is the world's largest society in diabetes and metabolic diseases, and it is known that fewer than the top 5% of all submitted studies receive an opportunity for an oral presentation.
PRT1309 is an antibody therapy candidate based on a GIPR (gastric inhibitory polypeptide receptor) antagonism mechanism. It was designed on the basis of genetic studies (GWAS) showing that reduced GIPR function is associated with weight loss.
Recently in the obesity drug market, there has been a shift from agonist-centered approaches to expansion using inhibitory principles. "MariTide," an obesity treatment candidate from Amgen in the United States, is in clinical development in the same class.
According to the company, PRT1309 is characterized by finely tuning antibody binding properties using Proteina's SPID platform and artificial intelligence (AI) design technology. It secures both productivity and binding stability compared with conventional antibodies, and reduces preclinical risk by selecting sequences with a high likelihood of development at an early stage. Antibodies that can bind in both humans and mice were derived, enabling preclinical experiments without using separate surrogate antibodies.
The company aims to secure in vivo data in the third quarter of this year and validate in a nonhuman primate model by year-end, and plans to pursue an investigational new drug (IND) application in 2027. A Proteina official said, "A meaningful achievement recognized for its technological prowess at the world's most prestigious society," and added, "We will translate this into rapid commercialization results."